Understanding when your key therapeutic competitors face patent cliffs and whether those cliffs have been extended by secondary patents, formulation patents, or pediatric exclusivity is directly commercially relevant to formulary strategy
24% in primary kidney outcome 29% in cardiovascular death 20% in all-cause mortality Read the full study here: nejm.org/doi/full/10.10 #MedTwitter #KidneyHealth #DiabetesResearch #HealthcareInnovation New @NEJM study reveals #Semaglutide (#Ozempic) significantly reduces risks of major kidney events, cardiovascular outcomes, and mortality in patients with type 2 #diabetes and chronic kidney disease
Finding Your Optimal Calorie Range on Semaglutide Most patients on semaglutide maintain weight loss when consuming between 1,200 and 1,800 calories daily, though individual needs vary widely based on age, activity level, starting weight, and metabolic health
Underlying Cause: Conditions like pernicious anemia or gastrointestinal disorders may slow recovery if not managed alongside the deficiency
